Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2012 1
2013 1
2014 2
2015 1
2016 1
2017 2
2021 0
Text availability
Article attribute
Article type
Publication date

Search Results

6 results
Results by year
Filters applied: . Clear all
Page 1
The checkpoint for agonist selection precedes conventional selection in human thymus.
Verstichel G, Vermijlen D, Martens L, Goetgeluk G, Brouwer M, Thiault N, Van Caeneghem Y, De Munter S, Weening K, Bonte S, Leclercq G, Taghon T, Kerre T, Saeys Y, Van Dorpe J, Cheroutre H, Vandekerckhove B. Verstichel G, et al. Among authors: van caeneghem y. Sci Immunol. 2017 Feb 24;2(8):eaah4232. doi: 10.1126/sciimmunol.aah4232. Sci Immunol. 2017. PMID: 28783686 Free PMC article.
Antigen receptor-redirected T cells derived from hematopoietic precursor cells lack expression of the endogenous TCR/CD3 receptor and exhibit specific antitumor capacities.
Van Caeneghem Y, De Munter S, Tieppo P, Goetgeluk G, Weening K, Verstichel G, Bonte S, Taghon T, Leclercq G, Kerre T, Debets R, Vermijlen D, Abken H, Vandekerckhove B. Van Caeneghem Y, et al. Oncoimmunology. 2017 Jan 19;6(3):e1283460. doi: 10.1080/2162402X.2017.1283460. eCollection 2017. Oncoimmunology. 2017. PMID: 28405508 Free PMC article.
In vitro human embryonic stem cell hematopoiesis mimics MYB-independent yolk sac hematopoiesis.
Vanhee S, De Mulder K, Van Caeneghem Y, Verstichel G, Van Roy N, Menten B, Velghe I, Philippé J, De Bleser D, Lambrecht BN, Taghon T, Leclercq G, Kerre T, Vandekerckhove B. Vanhee S, et al. Among authors: van caeneghem y. Haematologica. 2015 Feb;100(2):157-66. doi: 10.3324/haematol.2014.112144. Epub 2014 Nov 7. Haematologica. 2015. PMID: 25381126 Free PMC article.
In vitro generation of mature, naive antigen-specific CD8(+) T cells with a single T-cell receptor by agonist selection.
Snauwaert S, Verstichel G, Bonte S, Goetgeluk G, Vanhee S, Van Caeneghem Y, De Mulder K, Heirman C, Stauss H, Heemskerk MH, Taghon T, Leclercq G, Plum J, Langerak AW, Thielemans K, Kerre T, Vandekerckhove B. Snauwaert S, et al. Among authors: van caeneghem y. Leukemia. 2014 Apr;28(4):830-41. doi: 10.1038/leu.2013.285. Epub 2013 Oct 4. Leukemia. 2014. PMID: 24091848
Gene Correction of iPSCs from a Wiskott-Aldrich Syndrome Patient Normalizes the Lymphoid Developmental and Functional Defects.
Laskowski TJ, Van Caeneghem Y, Pourebrahim R, Ma C, Ni Z, Garate Z, Crane AM, Li XS, Liao W, Gonzalez-Garay M, Segovia JC, Paschon DE, Rebar EJ, Holmes MC, Kaufman D, Vandekerckhove B, Davis BR. Laskowski TJ, et al. Among authors: van caeneghem y. Stem Cell Reports. 2016 Aug 9;7(2):139-48. doi: 10.1016/j.stemcr.2016.06.003. Epub 2016 Jul 7. Stem Cell Reports. 2016. PMID: 27396937 Free PMC article.
RHAMM/HMMR (CD168) is not an ideal target antigen for immunotherapy of acute myeloid leukemia.
Snauwaert S, Vanhee S, Goetgeluk G, Verstichel G, Van Caeneghem Y, Velghe I, Philippé J, Berneman ZN, Plum J, Taghon T, Leclercq G, Thielemans K, Kerre T, Vandekerckhove B. Snauwaert S, et al. Among authors: van caeneghem y. Haematologica. 2012 Oct;97(10):1539-47. doi: 10.3324/haematol.2012.065581. Epub 2012 Apr 24. Haematologica. 2012. PMID: 22532518 Free PMC article.